ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1096

IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis

Renée Van der Cruyssen1, Djoere Gaublomme1, Emilie Dumas1, Carolien Vlieghe1, Flore Stappers2, Julie Coudenys1, Tine Decruy1, Lars Vereecke1, Eric Gracey1 and Dirk Elewaut3, 1VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, 2VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, 3Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium

Meeting: ACR Convergence 2022

Keywords: Animal Model, body mass, Bone density, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Spondyloarthritis Including PsA – Basic Science

Session Type: Abstract Session

Session Time: 10:30AM-11:30AM

Background/Purpose: IL-23 mediated inflammatory diseases such as psoriasis and psoriatic arthritis are associated with bone loss in addition to more classical features such as skin and joint inflammation. Inflammation-induced bone loss has long been assumed to be directly due to inflammatory cytokines, such as TNF or IL-17. Here, we provide evidence that inflammation-induced bone loss is mediated via the stress-induced cytokine, Growth Differentiation Factor 15 (GDF15). GDF15 is a well-known mediator of weight loss through aversion to food. It acts exclusively through a single receptor found in the hindbrain, GFRAL (glial cell line-derived neurotrophic factor (GDNF) family receptor α-like), which triggers systemic effects through activation of the sympathetic nervous system (Suriben et al. 2020. Nat Med).

Methods: GDF15 levels in SpA patients, selected by ASAS criteria, were determined using ELISA (R&D cat. DY957). Stable overexpression of GDF15 or IL-23 in mice was performed by using in-house designed EEV (Enhanced Episomal Vectors). GFRAL deficient mice were generated by CRISPR/Cas9 editing to evaluate the GFRAL dependency of GDF15 mediated effects. Systemic and joint Inflammation in mice was quantified clinically, and by histopathology, flow cytometry and RNA sequencing. Quantitative bone analysis was performed by µCT using an in-house developed script in FiJi software (FiJi is Just ImageJ).

Results: We found serum GDF15 to be elevated in spondyloarthritis patients, especially those with co-morbid psoriasis. We used GDF15-EEV to induce sustained, systemic overexpression of GDF15. GDF15 overexpression did not result in skin, gut or joint inflammation. As expected, GDF15 overexpression caused weight loss, however revealed dose-dependent GDF15-induced trabecular bone loss (Figure 1). Gene expression showed a marked upregulation in osteoclast genes. Intriguingly, caloric restriction alone was not able to replicate GDF15-induced trabecular bone loss, suggesting the existence of a GDF15 mediated brain-bone axis.

IL-23 overexpression by EEV causes psoriatic-like inflammation in mice, coupled with bone and weight loss. We found serum GDF15 to be increased in mice with elevated IL-23 (control: 45.51 +/- 2.774 ; IL-23: 91 +/- 11.71 pg/ml, p < 0.01), indicating IL-23 mediated induction of GDF15. To evaluate whether the IL-23 mediated bone loss was mediated by GDF15 we induced IL-23 overexpression in the absence of GDF15 or GFRAL. Curiously, both GDF15-KO and GFRAL-KO mice showed significant protection against IL-23 induced weight and bone loss but displayed no protection against skin inflammation (Figure 2: * p < 0,05, ** p < 0, 01).

Conclusion: GDF15 was found to be a novel regulator of bone homeostasis. IL-23 driven inflammation induces GDF15, which in turn mediates trabecular bone loss, but does not participate in inflammation severity. Collectively, these data suggest the existence of a brain-bone axis driving the IL-23 mediated bone loss in psoriasis and psoriatic arthritis.

Supporting image 1

Figure 1. GDF15-EEV induces dose-dependent trabecular bone loss in mice.

Supporting image 2

Figure 2. GFRAL-KO mice are significantly protected against IL_23 EEV induced weight loss and bone trabeculae bone loss, but not skin inflammation


Disclosures: R. Van der Cruyssen, None; D. Gaublomme, None; E. Dumas, None; C. Vlieghe, None; F. Stappers, None; J. Coudenys, None; T. Decruy, None; L. Vereecke, None; E. Gracey, None; D. Elewaut, AbbVie, Eli Lilly, Galapagos, Novartis, UCB Pharma.

To cite this abstract in AMA style:

Van der Cruyssen R, Gaublomme D, Dumas E, Vlieghe C, Stappers F, Coudenys J, Decruy T, Vereecke L, Gracey E, Elewaut D. IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/il-23-induced-growth-differentiation-factor-15-contributes-to-trabecular-bone-loss-but-does-not-affect-skin-gut-or-joint-inflammation-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-23-induced-growth-differentiation-factor-15-contributes-to-trabecular-bone-loss-but-does-not-affect-skin-gut-or-joint-inflammation-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology